Contrasting GlobeStar Therapeutics (OTCMKTS:GSTC) and Seelos Therapeutics (NASDAQ:SEEL)

GlobeStar Therapeutics (OTCMKTS:GSTCGet Rating) and Seelos Therapeutics (NASDAQ:SEELGet Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Profitability

This table compares GlobeStar Therapeutics and Seelos Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GlobeStar Therapeutics N/A N/A -68,657.57%
Seelos Therapeutics N/A -239.70% -132.82%

Risk & Volatility

GlobeStar Therapeutics has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500.

Valuation & Earnings

This table compares GlobeStar Therapeutics and Seelos Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GlobeStar Therapeutics N/A N/A -$9.80 million ($0.01) -0.53
Seelos Therapeutics $380,000.00 230.10 -$66.05 million ($0.79) -1.03

GlobeStar Therapeutics has higher earnings, but lower revenue than Seelos Therapeutics. Seelos Therapeutics is trading at a lower price-to-earnings ratio than GlobeStar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

0.0% of GlobeStar Therapeutics shares are owned by institutional investors. Comparatively, 29.6% of Seelos Therapeutics shares are owned by institutional investors. 5.1% of Seelos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for GlobeStar Therapeutics and Seelos Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GlobeStar Therapeutics 0 0 0 0 N/A
Seelos Therapeutics 0 0 2 0 3.00

Seelos Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 390.26%. Given Seelos Therapeutics’ higher probable upside, analysts clearly believe Seelos Therapeutics is more favorable than GlobeStar Therapeutics.

Summary

Seelos Therapeutics beats GlobeStar Therapeutics on 7 of the 11 factors compared between the two stocks.

About GlobeStar Therapeutics

(Get Rating)

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. The company was incorporated in 2016 and is based in Richland, Washington.

About Seelos Therapeutics

(Get Rating)

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Receive News & Ratings for GlobeStar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlobeStar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.